PROCLAIM: A phase 2, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to examine the effects of AC2592 [glucagon-like peptide 1] administered by continuous subcutaneous infusion in subjects with advanced chronic congestive heart failure

Trial Profile

PROCLAIM: A phase 2, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to examine the effects of AC2592 [glucagon-like peptide 1] administered by continuous subcutaneous infusion in subjects with advanced chronic congestive heart failure

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2015

At a glance

  • Drugs Glucagon-like peptide-1 (Primary)
  • Indications Chronic heart failure; Heart failure
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms PROCLAIM
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Feb 2008 The expected completion date for this trial is now 1 Sep 2006.
    • 26 Dec 2007 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 26 Dec 2007 Status change from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top